In the setting of secondary post-ACS prevention, what is your trigger for moving beyond a statin/ezetimibe combination to a PCSK9 inhibitor?

In the setting of secondary post-ACS prevention, what is your trigger for moving beyond a statin/ezetimibe combination to a PCSK9 inhibitor?

Get Credit

In the setting of secondary post-ACS prevention, what is your trigger for moving beyond a statin/ezetimibe combination to a PCSK9 inhibitor?

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Medical and Preventive Cardiologist's Perspective

Presenter

Dan Atar, MD

Dan Atar, MD

Head of Research Oslo University Hospital Ulleval Professor of Cardiology University of Oslo Oslo, Norway Visiting Associate Professorship Johns Hopkins University Baltimore, Maryland